Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
复方甲氧那明胶囊
- Development stage
- Unknown
- Lead developer
- Changxing Pharmaceutical
- Modality
- Drug Delivery Systems, Small Molecules
- Administration
- Oral
01
Overview
复方甲氧那明胶囊是一种口服多成分复合制剂，主要用于支气管哮喘、喘息性支气管炎及其他呼吸系统疾病引起的咳嗽、咳痰和喘息等症状。其活性成分包括盐酸甲氧那明（β-肾上腺素能受体激动剂，松弛支气管平滑肌）、那可丁（外周性止咳药）、氨茶碱（松弛支气管平滑肌并减轻黏膜充血水肿）和马来酸氯苯那敏（H1受体拮抗剂，对抗组胺反应）。该药通过多靶点协同作用，实现解痉平喘、止咳化痰及抗过敏等综合疗效[1][2][3][4][5].
- Brand names
- 阿斯美克之诺尔彤
- Other names
- Compound Methoxyphenamine Capsules复方甲氧那明
02
Targets
ADORA2A (Adenosine A₂A Receptor)HRH1 (Histamine H1 Receptor)ADORA1 (Adenosine receptor A1 subtype)ADRB2 (β2)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on 复方甲氧那明胶囊.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 复方甲氧那明胶囊.